Mark Bradley Spitzer

Learn More
A group of 146 experts representing 29 organizations and professional societies met September 18-19, 2006, in Bethesda, MD, to develop revised evidence-based, consensus guidelines for managing women with abnormal cervical cancer screening tests. Recommendations for managing atypical squamous cells of undetermined significance and low-grade squamous(More)
This paper reports on progress in the area of hardware for wearable computing. Our specific interest is in reducing conventional head-mounted display systems to eyeglass scale. We report here the successful demonstration of an ergonomic eyeglasses-based display. We present some of the general considerations in the design of such eyeglasses and briefly(More)
OBJECTIVE To provide updated consensus guidelines for the management of women with cervical intraepithelial neoplasia (CIN) or adenocarcinoma in situ (AIS). PARTICIPANTS A group of 146 experts including representatives from 29 professional organizations, federal agencies, and national and international health organizations met on September 18-19, 2006, in(More)
OBJECTIVE Visual assessment of digitized cervigrams through the Internet needs to be optimized. The National Cancer Institute and National Library of Medicine are involved in a large effort to improve colposcopic assessment and, in preparation, are conducting methodologic research. MATERIALS AND METHODS We selected 50 cervigrams with diagnoses ranging(More)
BACKGROUND Consensus United States cervical cancer screening guidelines recommend use of combination Pap plus human papillomavirus (HPV) testing for women aged 30 to 65 years. An HPV test was approved by the Food and Drug Administration in 2014 for primary cervical cancer screening in women age 25 years and older. Here, we present the results of(More)
S ince the publication of the 2001 consensus guidelines, new information has become available, which includes the key follow-up results from the National Cancer Institute (NCI)–sponsored ASCUS (atypical squamous cells of un-determined significance)/LSIL (low-grade squamous intraepithelial lesions) Triage Study (ALTS). 1,2 Moreover, molecular testing for(More)
  • 1